Strategies for Prevention and Management of Adverse Events

Video

Chung-Han Lee, MD, PhD, provides a commentary on strategies for preventing and managing treatment-related adverse events in metastatic RCC.

Related Videos
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Attending educational sessions may help with understanding how to manage toxicities associated with enfortumab vedotin in rare genitourinary cancers.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Related Content
Additionally, the 48-month overall survival rate was higher with nivolumab/cabozantinib vs sunitinib in the phase 3 CheckMate 9ER trial.

Frontline Nivolumab Combo Improves TFS Vs Sunitinib in Advanced RCC

Kyle Doherty
June 9th 2024
Article

Additionally, the 48-month overall survival rate was higher with nivolumab/cabozantinib vs sunitinib in the phase 3 CheckMate 9ER trial.

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Finding Ways to Break the Mold in GU Oncology

Maha H. Hussain, MD;Sarah E. Fenton, MD, PhD
April 8th 2024
Podcast

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Thrombocytopenia and interstitial lung disease following treatment with JNJ-6420 appeared to be manageable with dose schedule modifications.

HK2-Targeting Radioligand Shows Responses With Some AEs in Metastatic CRPC

Jordyn Sava
June 4th 2024
Article

Thrombocytopenia and interstitial lung disease following treatment with JNJ-6420 appeared to be manageable with dose schedule modifications.

OncView™ Podcast: Safety and Efficacy of Available Treatment Options and Considerations for Patient Management in Metastatic RCC

OncView™ Podcast: Safety and Efficacy of Available Treatment Options and Considerations for Patient Management in Metastatic RCC

David Aggen, MD, PhD;Robert S. Alter, MD;Arnab Basu, MD, MPH, FACP;Mehmet Asim Bilen, MD;Chung-Han Lee, MD, PhD, Memorial Sloan Kettering Cancer Center
June 2nd 2022
Podcast

In an OncView™ program, David H. Aggen, MD, PhD, Robert S. Alter, MD, Arnab Basu, MD, MPH, FACP, Mehmet Asim Bilen, MD, and Chung-Han Lee, MD, MPH, offer their expert insights for the treatment of RCC.

Phase 1/2 data support further development of ARV-766 in advanced prostate cancer, says Daniel P. Petrylak, MD.

Novel PROTAC Androgen Receptor Elicits Clinical Activity in Metastatic CRPC

Jonah Feldman
June 4th 2024
Article

Phase 1/2 data support further development of ARV-766 in advanced prostate cancer, says Daniel P. Petrylak, MD.

The rate of subsequent anticancer therapy was reduced with darolutamide vs placebo in patients with mHSPC in the ARASENS trial.

Time to Progression in mHSPC Cohort Prolonged With Darolutamide

Ben Saylor
June 3rd 2024
Article

The rate of subsequent anticancer therapy was reduced with darolutamide vs placebo in patients with mHSPC in the ARASENS trial.